Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;163(3-4):102-5.
doi: 10.1007/s10354-012-0166-0. Epub 2012 Dec 20.

Efficacy and Safety of Echinaforce® in Respiratory Tract Infections

Affiliations
Free PMC article
Review

Efficacy and Safety of Echinaforce® in Respiratory Tract Infections

Andreas Schapowal. Wien Med Wochenschr. .
Free PMC article

Abstract

Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.

Echinaforce® ist der standardisierte Extrakt von Echinacea purpurea (Bioforce, Schweiz). Jüngste Studien zeigen eine Immunmodulation und breite antivirale Effekte gegen Atemwegsviren. Hä-magglutinin und Neuraminidase werden blockiert. Im Gegensatz zu Oseltamivir bewirkt Echinaforce® keine Resistenz. Eine randomisierte, plazbokontrollierte Doppelblindstudie über vier Monate bestätigt, dass Echinaforce® die Immunabwehr unterstützt und direkt gegen häufige Atemwegsviren wirkt. Echinaforce® ist bei Atemwegsinfekten effizient und sicher in der Langzeit- und Kurzzeit-Prävention, sowie in der Akutbehandlung.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Arch Fam Med. 2000;9(90):913–922. doi: 10.1001/archfami.9.9.913. - DOI - PubMed
    1. Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003;10:193–202. doi: 10.1097/00045391-200305000-00006. - DOI - PubMed
    1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey 1996. In: Vital and Health Statistics Series 10. Data from the National Health Survey; 1999. pp. 1–203. - PubMed
    1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494. doi: 10.1001/archinte.163.4.487. - DOI - PubMed
    1. Johnston SL. Problems and prospects of developing effective therapy for common cold viruses. Trends Microbiol. 1997;5(2):58–63. doi: 10.1016/S0966-842X(96)10082-2. - DOI - PMC - PubMed

MeSH terms

Feedback